Researchers have found a functional link between gut bacteria and Parkinson's disease. » Read More
By: Elizabeth Gurdus
Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful. » Read More
Shares of Bluebird were up more than 24 percent in premarket trade Thursday. » Read More
By: Aneri Pattani
Scientists are taking a new approach to the riddle of preterm birth, which kills 1 million babies globally each year. » Read More
"Most Americans hate their insurance and they hate the health-care system. It's unaffordable and it needs to be fixed," Aetna's Mark Bertolini says.
President-elect Donald Trump's proposal to overhaul Medicaid funding could force states to raise taxes or cut spending.
Whether Donald Trump repeals Obamacare or simply fixes it, either way, the system needs restructuring, Centene chief Michael Neidorff tells CNBC.
Valeant shares were down 22 percent on Tuesday, but Wells Fargo's David Maris says the company still has some time to right the ship.
Senior Research Analyst David Amsellem says, "We had never viewed the previous ranges as credible."
Valeant Pharmaceuticals reported an 11 percent fall in quarterly revenue due to faltering sales, and cut its full-year profit and revenue forecasts.
A U.S. Senate committee urged regulators to launch a probe into whether EpiPen maker Mylan broke the law by preventing schools from purchasing competing allergy treatments.
More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.
Just 4 percent of people can define all four terms that determine how much they would pay out of pocket for health services.
Drugmaker Mylan may have overcharged hospitals that serve significant numbers of poor people for lifesaving anti-allergy devices.
Pharmaceutical stocks have been under pressure, but certain companies are doing things right, former Medtronic CEO Bill George says.
The West Virginia attorney general says Mylan could be liable for more than the $465 million the company agreed to pay.
Anthem said sales of Obamacare plans have been disappointing to date, and the company could pull back its business in those plans in 2018.
The deal could include $8.5 billion in cash as well as future royalty payments for the embattled pharmaceutical company.
The Republican presidential nominee is hoping that stories about rising Obamacare rates will help him with voters next Tuesday.
Billionaire investor and Hillary Clinton-supporter Mark Cuban said that Donald Trump has no idea how Obamacare works.
Get the best of CNBC in your inbox